Proto oncogene/eukaryotic translation initiation factor (eIF) 4E attenuates mevalonate-mediated regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase synthesis

Molecular Carcinogenesis

Volumn 41, Issue 1, 2004, Pages 39-53

  Buechler, Robbie D ^a   Peffley, Dennis M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

5 untranslated regions; Isoprenoids; M7GpppX cap dependent translation; Mevalonate; mTOR

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOPRENOID; MEVALONIC ACID; MEVINOLIN; RAPAMYCIN; RETROVIRUS VECTOR; STEROL;

5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CELL CYCLE; CELL GROWTH; CELL SURVIVAL; CHO CELL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SYNTHESIS; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E GENE; GENE; GENE OVEREXPRESSION; M7 GPPX CAP DEPENDENT TRANSLATION; MITOGENESIS; NONHUMAN; POLYSOME; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTO ONCOGENE; RNA ISOLATION; TRANSCRIPTION REGULATION; TRANSLATION INITIATION; TRANSLATION REGULATION;

ANIMALS; CHO CELLS; CRICETINAE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MEVALONIC ACID; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; PROTO-ONCOGENES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION;

EUKARYOTA; MAMMALIA;

EID: 4444221115     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20039     Document Type: Article

References (92)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
2. Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 1995;270:17508-17512.
3. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-3609.
4. DeClue JE, Vass WC, Papageorge AG, Lowy DR, Willumsen BM. Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 1991;51:712-717.
5. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 1991;88:3628-3632.
6. Schulz S, Buhling F, Ansorge S. Prenylated proteins and lymphocyte proliferation: Inhibition by D-limonene related monoterpenes. Eur J Immunol 1994;24:301-307.
7. Shoff SM, Grummer M, Yatvin MB, Elson CE. Concentration-dependent increase of murine P388 and B16 population doubling time by the acyclic monoterpene geraniol. Cancer Res 1991;51:37-42.
8. Yu SG, Hildebrandt LA, Elson CE. Geraniol, an inhibitor of mevalonate biosynthesis, suppresses the growth of hepatomas and melanomas transplanted to rats and mice. J Nutr 1995;125:2763-2767.
9. Elson CE, Peffley DM, Hentosh P, Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: Potential application to cancer. Proc Soc Exp Biol Med 1999;221:294-311.
10. Mo H, Elson CE. Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. J Nutr 1999;129:804-813.
11. Hentosh P, Yuh SH, Elson CE, Peffley DM. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 2001;32:154-166.
12. Peffley D, Sinensky M. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis by a non-sterol mevalonate-derived product in Mev-1 cells. Apparent translational control. J Biol Chem 1985;260:9949-9952.
13. Peffley DM. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis in Syrian hamster C100 cells by mevinolin, 25-hydroxycholesterol, and mevalonate: The role of posttranscriptional control. Somat Cell Mol Genet 1992;18:19-32.
14. Peffley DM, Gayen AK. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level. Arch Biochem Biophys 1997;337:251-260.
15. Nakanishi M, Goldstein JL, Brown MS. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J Biol Chem 1988;263:8929-8937.
16. Choi JW, Peffley DM. 3′-untranslated sequences mediate post-transcriptional regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA by 25-hydroxycholesterol. Biochem J 1995;307:233-238.
17. Choi JW, Lundquist EN, Peffley DM. Inhibition of protein synthesis in baby-hamster kidney cells blocks oxysterol-mediated suppression of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA at a post-transcriptional level. Biochem J 1993;296:859-866.
18. Vallett SM, Sanchez HB, Rosenfeld JM, Osborne TF. A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3- methylglutaryl coenzyme A reductase gene. J Biol Chem 1996;271:12247-12253.
19. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA 1999;96:11041-11048.
20. Meigs TE, Simoni RD. Farnesol as a regulator of HMG-CoA reductase degradation: Characterization and role of farnesyl pyrophosphatase. Arch Biochem Biophys 1997;345:1-9.
21. Correll CC, Ng L, Edwards PA. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 1994;269:17390-17393.
22. Gardner RG, Shearer AG, Hampton RY. In vivo action of the HRD ubiquitin ligase complex: Mechanisms of endoplasmic reticulum quality control and sterol regulation. Mol Cell Biol 2001;21:4276-4291.
23. Moriyama T, Wada M, Urade R, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase is sterol-dependently cleaved by cathepsin L-type cysteine protease in the isolated endoplasmic reticulum. Arch Biochem Biophys 2001;386:205-212.
24. Sever N, Yang T, Brown MS, Goldstein JL, DeBose-Boyd RA. Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. Mol Cell 2003;11:25-33.
25. Peffley DM, Gayen AK. Mevalonate regulates polysome distribution and blocks translation-dependent suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA: Relationship to translational control. Somat Cell Mol Genet 1995;21:189-204.
26. Peffley DM, Gayen AK. Plant-derived monoterpenes suppress hamster kidney cell 3-hydroxy-3-methylglutaryl coenzyme a reductase synthesis at the post-transcriptional level. J Nutr 2003;133:38-44.
27. Peffley DM, Gayen AK, Morand OH. Down-regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase mRNA levels and synthesis in Syrian hamster C100 cells by the oxidosqualene cyclase inhibitor [4′-(6-allyl-ethyl- amino-hexyloxy)-2′-fluoro-phenyl]-(4-bromophenyl)-methanone (Ro 48-8071): Comparison to simvastatin. Biochem Pharmacol 1998;56:439-449.
28. Pain VM. Initiation of protein synthesis in eukaryotic cells. Eur J Biochem 1996;236:747-771.
29. Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998;10:268-275.
30. Jackson RJ, Wickens M. Translational controls impinging on the 5′-untranslated region and initiation factor proteins. Curr Opin Genet Dev 1997;7:233-241.
31. Kozak M. Initiation of translation in prokaryotes and eukaryotes. Gene 1999;234:187-208.
32. Sonenberg N, Dever TE. Eukaryotic translation initiation factors and regulators. Curr Opin Struct Biol 2003;13:56-63.
33. Lawrence JC, Jr., Abraham RT. PHAS/4E-BPs as regulators of mRNA translation and cell proliferation. Trends Biochem Sci 1997;22:345-349.
34. Svitkin YV, Ovchinnikov LP, Dreyfuss G, Sonenberg N. General RNA binding proteins render translation cap dependent. Embo J 1996;15:7147-7155.
35. Rousseau D, Kaspar R, Rosenwald I, Gehrke L, Sonenberg N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci USA 1996;93:1065-1070.
36. Hayashi S, Nishimura K, Fukuchi-Shimogori T, Kashiwagi K, Igarashi K. Increase in cap- and IRES-dependent protein synthesis by overproduction of translation initiation factor eIF4G. Biochem Biophys Res Commun 2000;277:117-123.
37. Shantz LM, Hu RH, Pegg AE. Regulation of ornithine decarboxylase in a transformed cell line that overexpresses translation initiation factor eIF-4E. Cancer Res 1996;56:3265-3269.
38. Fagan RJ, Lazaris-Karatzas A, Sonenberg N, Rozen R. Translational control of ornithine aminotransferase. Modulation by initiation factor eIF-4E. J Biol Chem 1991;266:16518-16523.
39. Nathan CA, Franklin S, Abreo FW, et al. Expression of eIF4E during head and neck tumorigenesis: Possible role in angiogenesis. Laryngoscope 1999;109:1253-1258.
40. Nathan CA, Carter P, Liu L, et al. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 1997;15:1087-1094.
41. Kevil C, Carter P, Hu B, DeBenedetti A. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene 1995;11:2339-2348.
42. Topisirovic I, Culjkovic B, Cohen N, Ferez JM, Skrabanek L, Borden KL. The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth. Embo J 2003;22:689-703.
43. Tan A, Bitterman P, Sonenberg N, Peterson M, Polunovsky V. Inhibition of myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene 2000;19:1437-1447.
44. Abid MR, Li Y, Anthony C, De Benedetti A. Translational regulation of ribonucleotide reductase by eukaryotic initiation factor 4E links protein synthesis to the control of DNA replication. J Biol Chem 1999;274:35991-35998.
45. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM. Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: A survival mechanism for carcinoma cells. J Cell Biol 2002;158:165-174.
46. Scott PA, Smith K, Poulsom R, De Benedetti A, Bicknell R, Harris AL. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 1998;77:2120-2128.
47. von Manteuffel SR, Dennis PB, Pullen N, Gingras AC, Sonenberg N, Thomas G. The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol Cell Biol 1997;17:5426-5436.
48. De Benedetti A, Harris AL. eIF4E expression in tumors: Its possible role in progression of malignancies. Int J Biochem Cell Biol 1999;31:59-72.
49. Sorrells DL, Jr., Ghali GE, De Benedetti A, Nathan CA, Li BD. Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers. J Oral Maxillofac Surg 1999;57:294-299.
50. Miyagi Y, Sugiyama A, Asai A, Okazaki T, Kuchino Y, Kerr SJ. Elevated levels of eukaryotic translation initiation factor eIF4E, mRNA in a broad spectrum of transformed cell lines. Cancer Lett 1995;91:247-252.
51. Herbert TP, Fahraeus R, Prescott A, Lane DP, Proud CG. Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol 2000;10:793-796.
52. Polunovsky VA, Rosenwald IB, Tan AT, et al. Translational control of programmed cell death: Eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated myc. Mol Cell Biol 1996;16:6573-6581.
53. Polunovsky VA, Gingras AC, Sonenberg N, et al. Translational control of the antiapoptotic function of Ras. J Biol Chem 2000;275:24776-24780.
54. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Jr., Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. Embo J 1996;15:5256-5267.
55. Miron M, Verdu J, Lachance PE, Birnbaum MJ, Lasko PF, Sonenberg N. The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in Drosophila. Nat Cell Biol 2001;3:596-601.
56. von Manteuffel SR, Gingras AC, Ming XF, Sonenberg N, Thomas G. 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc Natl Acad Sci USA 1996;93:4076-4080.
57. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998;95:1432-1437.
58. Thimmaiah KN, Easton J, Huang S, et al. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways. Cancer Res 2003;63:364-374.
59. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997;275:665-668.
60. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-826.
61. Haydon MS, Googe JD, Sorrells DS, Ghali GE, Li BD. Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer 2000;88:2803-2810.
62. Reynolds GA, Goldstein JL, Brown MS. Multiple mRNAs for 3-hydroxy-3-methylglutaryl coenzyme A reductase determined by multiple transcription initiation sites and intron splicing sites in the 5′-untranslated region. J Biol Chem 1985;260:10369-10377.
63. DeFatta RJ, Turbat-Herrera EA, Li BD, Anderson W, De Benedetti A. Elevated expression of eIF4E in confined early breast cancer lesions: Possible role of hypoxia. Int J Cancer 1999;80:516-522.
64. Kerekatte V, Smiley K, Hu B, Smith A, Gelder F, De Benedetti A. The proto-oncogene/translation factor eIF4E: A survey of its expression in breast carcinomas. Int J Cancer 1995;64:27-31.
65. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990;345:544-547.
66. Kirschmeier PT, Mousey GM, Johnson MD, Perkins AS, Weinstein IB. Construction and characterization of a retroviral vector demonstrating efficient expression of cloned cDNA sequences. DNA 1988;7:219-225.
67. Shantz LM, Pegg AE. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res 1994;54:2313-2316.
68. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
69. Krieg PA, Melton DA. Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res 1984;12:7057-7070.
70. Correll CC, Edwards PA. Mevalonic acid-dependent degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo and in vitro. J Biol Chem 1994;269:633-638.
71. Peffley D, Miyake J, Leonard S, von Gunten C, Sinensky M. Further characterization of a somatic cell mutant defective in regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Somat Cell Mol Genet 1988;14:527-539.
72. Graves LM, Bornfeldt KE, Argast GM, et al. cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc Natl Acad Sci USA 1995;92:7222-7226.
73. Jones RM, Branda J, Johnston KA, et al. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol 1996;16:4754-4764.
74. Rousseau D, Gingras AC, Pause A, Sonenberg N. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 1996;13:2415-2420.
75. Reynolds GA, Basu SK, Osborne TF, et al. HMG CoA reductase: A negatively regulated gene with unusual promoter and 5′ untranslated regions. Cell 1984;38:275-285.
76. Aboushadi N, Shackelford JE, Jessani N, Gentile A, Krisans SK. Characterization of peroxisomal 3-hydroxy-3-methylglutaryl coenzyme A reductase in UT2 cells: Sterol biosynthesis, phosphorylation, degradation, and statin inhibition. Biochemistry 2000;39:237-247.
77. Lazaris-Karatzas A, Sonenberg N. The mRNA 5′ cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol Cell Biol 1992;12:1234-1238.
78. Kaufman RJ, Murtha-Riel P, Pittman DD, Davies MV. Characterization of wild-type and Ser53 mutant eukaryotic initiation factor 4E overexpression in mammalian cells. J Biol Chem 1993;268:11902-11909.
79. Flynn A, Proud CG. Serine 209, not serine 53, is the major site of phosphorylation in initiation factor eIF-4E in serum-treated Chinese hamster ovary cells. J Biol Chem 1995;270:21684-21688.
80. Joshi B, Cai AL, Keiper BD, et al. Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J Biol Chem 1995;270:14597-14603.
81. Scheper GC, van Kollenburg B, Hu J, Luo Y, Goss DJ, Proud CG. Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA. J Biol Chem 2002;277:3303-3309.
82. Lachance PE, Miron M, Raught B, Sonenberg N, Lasko P. Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth. Mol Cell Biol 2002;22:1656-1663.
83. Gayen AK, Peffley DM. The length of 5′-untranslated leader sequences influences distribution of 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in polysomes: Effects of lovastatin, oxysterols, and mevalonate. Arch Biochem Biophys 1995;322:475-485.
84. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. Embo J 1997;6:3693-3704.
85. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 1993;268:11230-11238.
86. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. Embo J 1996;15:658-664.
87. Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331-340.
88. Sinensky M, Fantle K, Dalton M. An antibody which specifically recognizes prelamin A but not mature lamin A: Application to detection of blocks in farnesylation-dependent protein processing. Cancer Res 1994;54:3229-3232.
89. Joneson T, Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. J Mol Med 1997;75:587-593.
90. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. Embo J 1997;16:2783-2793.
91. Asslan R, Pradines A, Favre G, Le Gaillard F. Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells. Biochem J 1998;330:241-246.
92. Carlberg M, Drieu A, Biegen H, et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem 1996;271:17453-17462.